Effects of Sodium-Glucose Co-transporter 2 Inhibitors on Inflammation

Part of paid clinical trials in St Louis, Missouri.

Sponsor
Washington University School of Medicine
Study ID
NCT06812429
Phase
EARLY_PHASE1
Status
Completed

Conditions

  • Inflammation

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • Dapagliflozin (DAPA) — DRUG
    Participants will receive 10mg of Dapagliflozin per day for three days.

Study Details

The research aims to understand how a specific type of medication called Sodium-glucose co-transporter 2 (SGLT2) inhibitors affect cardiorenal inflammation.

Key Dates

First listed
Feb 6, 2025
Start date
May 8, 2024
Status verified
Jan 2026
Primary completion
Apr 5, 2025
Completion
Apr 5, 2025

Study Design

Enrollment
6 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Dapagliflozin group
    Participants in this arm receive dapagliflozin 10mg for three days.

Primary Outcome Measure

Change from baseline in the markers of Inflammation at three days [ Time Frame: From enrollment to the end of treatment at 3 days. ]

Locations (1)

FacilityCityStateZIPSite coordinators
Washington UniversitySt LouisMissouri63110-

Find similar trials in St Louis, MO

By research site
Washington University· St Louis, MO

Related Studies